Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news earnings_data wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi drug-approval timing question, so the market's own price is the primary anchor, supplemented by news on COMPASS Pathways' COMP360 Phase 3 readouts (COMP005/COMP006), NDA submission guidance, and any breakthrough-therapy/priority-review signals. The key arithmetic is whether an NDA can be filed and reviewed (10-12 month standard, 6-8 month priority) before July 1, 2027.

# Current state Kalshi's own market prices "Yes" (FDA approval before July 1, 2027) at 79%, up 5pts over 30 days, reflecting COMPASS Pathways' Commissioner's National Priority Voucher (CNPV, granted April 2026) that can compress FDA review to 1-2 months, plus rolling-review status and two positive Phase 3 trials. The company has NOT yet submitted a complete NDA — sections are being filed under rolling review, with the final piece guided for Q4 2026, meaning the FDA "clock" for even an accelerated 1-2 month review likely doesn't fully start until late 2026, leaving a tight but plausible window before the July 2027 deadline. # Timeline of key events - 2018: FDA grants COMP360 Breakthrough Therapy Designation for TRD (confirmed, Wikipedia/SEC). - 2025-06: COMP005 Phase 3 (trial 1) meets primary endpoint at 6 weeks (MADRS reduction vs placebo); 26-week durability confirmed (confirmed, Medscape/company IR). - 2026-02: COMP006 Phase 3 (trial 2) meets primary endpoint, p<0.001, -3.8 pt MADRS difference at 6 weeks (confirmed, SEC 10-Q). - 2026-04-18: Trump executive order directs federal agencies to accelerate review of psychedelic drug therapies (reported, Medical Daily). - 2026-04-24: FDA issues Commissioner's National Priority Voucher (CNPV) to COMP360 program, compressing standard 10-12 month review to 1-2 months post-complete-NDA (reported, SEC/Medical Daily). - 2026 (date unspecified, post-CNPV): FDA grants rolling review request (confirmed, SEC 10-Q). - ~2026-07: COMP006 26-week durability/safety data released (~600 patients; 39% achieving ≥25% MADRS reduction sustained to Week 26; SAEs 5.7-6.3%) (confirmed, Psychiatric Times). - 2026-06 to present: Company guidance — rolling NDA underway, final submission targeted Q4 2026, potential US launch H1 2027 "subject to FDA approval and DEA rescheduling" (reported, multiple SEC/8-K sources). - 2026-06-17: FDA Commissioner Makary reportedly signals a decision could come "late summer or fall 2026" — inconsistent with Q4 2026 filing guidance, treat as rumored/optimistic (Medical Daily). # Event Will the FDA approve COMP360 psilocybin for treatment-resistant depression (marketing approval) before July 1, 2027? # Outcomes to forecast Yes / No # Kalshi market anchor Current YES price: **79%** (as of latest data). 7-day change: +1pt; 30-day change: +5pt. Price range over past 28 days: 69%-94% (notable volatility). Average daily volume: 75 contracts (thin liquidity) — price should be treated as informative but not fully efficient given low volume and wide range. # Sub-question answers 1. **Kalshi price/trend** — 79% YES, +5pts over 30 days, range 69-94% over 28 days; thin volume (~75 contracts/day) [kalshi_direct]. 2. **Phase 3 completion/results** — Both pivotal trials complete and positive: COMP005 (6-wk primary endpoint met June 2025, 26-wk durability confirmed) and COMP006 (6-wk primary endpoint met Feb 2026, p<0.001; 26-wk data ~July 2026 confirming durability, SAEs 5.7-6.3%) [claude_news/SEC/Medscape/Psychiatric Times]. 3. **NDA submission guidance** — Rolling NDA in progress with sections already filed; final submission guided for Q4 2026; potential US launch H1 2027 [SEC 8-K/10-Q, Medical Daily]. 4. **Breakthrough Therapy/review pathway** — Yes, BTD held since 2018 and active; additionally received CNPV (April 2026) which can compress review to 1-2 months post-complete-NDA, effectively faster than standard priority review (6-8mo) [claude_news, SEC]. 5. **Backward-dated deadline** — With CNPV's 1-2 month review, a complete NDA filed by ~April-May 2027 could still theoretically clear before July 2027; company's own Q4 2026 filing guidance is comfortably consistent with a pre-July-2027 approval if the voucher timeline holds and no CRL occurs. 6. **Base rates/DEA rescheduling** — No explicit first-cycle CNS approval base rate found in research; Wikipedia notes ~30% or less of drug candidates reach approved NDA overall (not first-cycle specific). DEA Schedule I rescheduling is flagged as a separate hurdle affecting commercial launch, but this market resolves on FDA marketing approval, not DEA rescheduling completion — so rescheduling delay may not block resolution [Wikipedia, Medical Daily]. 7. **Other markets** — No Polymarket matches found. Related Kalshi psychedelic/CNS markets: MDMA-for-PTSD (56% YES, before 2030), VERVE-102 (50%), Type 1 diabetes cure (41%) — not directly comparable tenors but show general skepticism on CNS/novel-drug approvals in this market family [kalshi_related, polymarket_related]. # Key facts (high-confidence, factual) 1. [SEC/Wikipedia] BTD granted 2018, remains active. 2. [SEC 10-Q] Both Phase 3 trials (COMP005, COMP006) met primary endpoints with statistically significant, durable results through 26 weeks. 3. [SEC/Medical Daily] CNPV granted April 24, 2026, following April 18 executive order — can compress review to 1-2 months post-complete NDA. 4. [SEC 10-Q] FDA granted rolling review; final NDA submission targeted Q4 2026. 5. [Medical Daily] Commercial launch guidance is H1 2027, explicitly conditioned on both FDA approval and DEA rescheduling. # Cross-market signals - Kalshi related: MDMA-for-PTSD 56% (longer horizon, to 2030); no direct COMP360-series comparables besides this ticker itself. - Polymarket: No active markets found on this topic. - Sportsbook implied: N/A (not applicable to FDA events). # Analyst opinions and speculation - Jefferies reportedly supportive post-COMP006 data (proactiveinvestors, July 2026), viewing data quality favorably. - Independent Monte Carlo model (code_execution) estimates only ~19% probability of approval before July 2027, with wide sensitivity range (8%-32%), driven by submission-timing uncertainty — this conflicts sharply with Kalshi's 79%. The model appears to underweight/not fully incorporate the CNPV's dramatic review-compression mechanism (1-2 months vs. standard 6-12), which is the key structural fact justifying the market's much higher price. - Some outlets (Medical Daily) speculate a decision as early as "late summer/fall 2026" — likely overly aggressive given Q4 2026 filing guidance; treat as rumored upside case. # Directional lean per outcome - **Yes**: Strong Phase 3 data, active BTD, rolling review granted, and CNPV compressing review timeline are structural tailwinds; company guidance (Q4 2026 filing, H1 2027 launch) is arithmetically consistent with pre-July-2027 approval. Kalshi market (79%) and news momentum both lean Yes. - **No**: Any slippage in Q4 2026 filing into 2027, a Complete Response Letter (CRL), or the CNPV's 1-2 month promise not materializing in practice would push approval past July 2027. Generic base-rate/Monte Carlo modeling suggests meaningfully lower probability (~19%) if CNPV benefit is discounted. # Gaps / unknowns - No confirmed exact NDA completion date or FDA acceptance date. - Unclear whether CNPV's "1-2 month" review promise has been tested/validated on any completed drug application yet. - DEA rescheduling status/timeline not detailed — could affect launch but likely not FDA approval resolution itself. - Discrepancy between Kalshi (79%) and independent simulation (~19%) not fully reconciled; likely explained by simulation not fully modeling CNPV impact. # Calibration anchors - Kalshi current YES price: **79%** (primary anchor, thin volume caveat). - Monte Carlo/base-rate model: ~15-20% central estimate (pre-CNPV-adjusted logic), range 8-32%. - Historical overall NDA success rate ~30% or less (general, not first-cycle/CNS specific) [Wikipedia].

1. Both forecasts converge tightly (0.75/0.74) around a shaded-down Kalshi anchor, but neither seriously engages with the Monte Carlo's structural argument that submission-timing uncertainty alone (Q4 2026 target with typical biotech slippage) could push the "clock start" past the point where even a 1-2 month CNPV review closes before July 2027 — this isn't just "ignoring CNPV," it's a legitimate concern about buffer thinness that deserves more than a passing dismissal. 2. Neither forecaster quantifies the margin: if final NDA sections are guided for Q4 2026 (say, October-December) and even the compressed review takes 1-2 months, that leaves potentially 5-9 months of buffer before July 2027, but any slip of the "final piece" into Q1 2027 (common for rolling submissions) sharply compresses or eliminates this margin — the brief explicitly flags this as "a tight but plausible window," which both forecasts underweight as a binary risk rather than a continuous timing distribution. 3. Both forecasts mention the CNPV's "untested" nature as a discount factor but don't consider the base-rate concern that no drug has ever completed the 1-2 month CNPV review yet — this is a mechanism with zero track record, and Schedule I psychedelics requiring REMS programs are exactly the kind of complex case where such compressed timelines could break down. 4. Neither forecast addresses the MDMA-for-PTSD precedent with sufficient weight — Forecast 1 mentions it in passing ("functional-unblinding critiques can sink a psychedelic NDA") but doesn't translate this into a concrete probability adjustment, even though it's the single most relevant reference class (a psychedelic-assisted therapy NDA that failed at the FDA/advisory-committee stage) and could suggest higher CRL risk than generic CNS base rates imply. 5. Both forecasts treat the Kalshi price as fairly efficient despite the brief's explicit caveat about thin volume (~75 contracts/day) and a wide 69-94% range over 28 days — given this volatility and low liquidity, anchoring within 4-5 points of 79% may overstate confidence in the market's informativeness rather than genuinely independently triangulating a value. 6. Neither forecast explores the tail scenario where COMP006's 26-week durability data (39% response rate, 5.7-6.3% SAEs) proves insufficiently differentiated or raises safety flags at an advisory committee, a scenario that could trigger a CRL/delay wholly independent of NDA-completion timing — this is a distinct failure mode from "slippage" that deserves separate probability mass in the No case.

70% (62% confidence)

Yes: 70% No: 30%

The structural case for Yes is strong: two positive, durable Phase 3 trials, active BTD, rolling review underway, a CNPV that can compress review to 1-2 months, and explicit political tailwinds — with Q4 2026 final submission guidance leaving a 5-8 month buffer to July 2027. However, the critique is right that both forecasts under-weight compounding risks: rolling-submission slippage into Q1 2027 is common, the CNPV's 1-2 month promise has zero completed track record (especially for a Schedule I drug needing a complex REMS), and the MDMA-for-PTSD precedent shows psychedelic NDAs can be derailed at advisory committee over functional unblinding and modest effect sizes (COMP006's -3.8 MADRS points, 39% sustained response is not overwhelming). Multiplying plausible sub-probabilities (filing complete in time ~0.85, review actually fast enough ~0.80-0.85, first-cycle approval rather than CRL ~0.85) yields something in the 0.60-0.65 range, below both the market and the two forecasts. Given the thin Kalshi liquidity (~75 contracts/day, 69-94% range) I don't treat 79% as fully efficient, but I also don't fully discount it, so I settle modestly below both prior forecasts at 0.70.

Total pipeline time: 294.3s